Replies to post #127820 on Biotech Values

[JJM760]

From Mrk's perspective, why not give it a shot? Worst they could say is no and you get the standard 10 month anyway.

Kinda like you'll never know if the hot chick at the end of the bar digs you unless you go over and say hi.

Thanks for the follow up.

[NP1986]

It will be interesting to see if Votrient gets a priority review from the FDA. Granted it is for second line therapy of sarcomas where there does seem to be an unmet need.

I don't think maintenance therapy really qualifies as an "unmet need" which could be why the FDA did not grant priority review for ridaforolimus.